Minimising uncertainty for biopharmaceutical payers and manufacturers is a key factor in maximising pricing and market access of orphan drugs.

Orphan drugs are not developed with the assurance of a large return on investment, and drug developers face an increasingly complex environment. Increasingly difficult regulatory hurdles, tougher competition and rising costs are just some of the challenges facing manufacturers today.

Furthermore, orphan drugs face difficulties related to their small patient populations and lack of comparative clinical trials. For payers, the small sample size and limited number of other treatment options provides high uncertainty on the clinical and economic evidence. For manufacturers, navigating the nuances of the orphan drug HTA process in each market, combined with a lack of relevant comparators, makes it challenging for payers and manufacturers alike to make informed decisions about orphan drug pricing and market access.

This webinar discussed the key issues in pricing, market access, and value assessment of orphan drugs. We demonstrated how GPI horizon methodology can be applied to forecast prices and payer-perceived value of an asset within a variety of scenarios.

Agenda:
- Current and future challenges and opportunities to pricing and market access of orphan drugs
- Use case of GPI horizon for an orphan asset
- Demonstration of how different TPP scenarios and price settings are incorporated into GPI horizon

свернуть